JP2022545917A5 - - Google Patents

Info

Publication number
JP2022545917A5
JP2022545917A5 JP2022513154A JP2022513154A JP2022545917A5 JP 2022545917 A5 JP2022545917 A5 JP 2022545917A5 JP 2022513154 A JP2022513154 A JP 2022513154A JP 2022513154 A JP2022513154 A JP 2022513154A JP 2022545917 A5 JP2022545917 A5 JP 2022545917A5
Authority
JP
Japan
Prior art keywords
cancer
tff2
modified
polypeptide
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022513154A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022545917A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/000699 external-priority patent/WO2021038296A2/en
Publication of JP2022545917A publication Critical patent/JP2022545917A/ja
Publication of JP2022545917A5 publication Critical patent/JP2022545917A5/ja
Priority to JP2025086620A priority Critical patent/JP2025158975A/ja
Pending legal-status Critical Current

Links

JP2022513154A 2019-08-27 2020-08-27 修飾tff2ポリペプチド Pending JP2022545917A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025086620A JP2025158975A (ja) 2019-08-27 2025-05-23 修飾tff2ポリペプチド

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962892520P 2019-08-27 2019-08-27
US62/892,520 2019-08-27
US201962943803P 2019-12-04 2019-12-04
US62/943,803 2019-12-04
US202063041097P 2020-06-18 2020-06-18
US63/041,097 2020-06-18
PCT/IB2020/000699 WO2021038296A2 (en) 2019-08-27 2020-08-27 Modified tff2 polypeptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025086620A Division JP2025158975A (ja) 2019-08-27 2025-05-23 修飾tff2ポリペプチド

Publications (2)

Publication Number Publication Date
JP2022545917A JP2022545917A (ja) 2022-11-01
JP2022545917A5 true JP2022545917A5 (cg-RX-API-DMAC7.html) 2023-09-05

Family

ID=72659816

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022513154A Pending JP2022545917A (ja) 2019-08-27 2020-08-27 修飾tff2ポリペプチド
JP2025086620A Pending JP2025158975A (ja) 2019-08-27 2025-05-23 修飾tff2ポリペプチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025086620A Pending JP2025158975A (ja) 2019-08-27 2025-05-23 修飾tff2ポリペプチド

Country Status (9)

Country Link
US (1) US20220281939A1 (cg-RX-API-DMAC7.html)
EP (1) EP4021479A2 (cg-RX-API-DMAC7.html)
JP (2) JP2022545917A (cg-RX-API-DMAC7.html)
CN (1) CN115551530A (cg-RX-API-DMAC7.html)
AU (1) AU2020338947B2 (cg-RX-API-DMAC7.html)
CA (1) CA3152665A1 (cg-RX-API-DMAC7.html)
IL (1) IL290910A (cg-RX-API-DMAC7.html)
MX (1) MX2022002337A (cg-RX-API-DMAC7.html)
WO (1) WO2021038296A2 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022240649A1 (en) * 2021-05-12 2022-11-17 Alkahest, Inc. Methods and compositions for treating aging-associated impairments with trefoil factor family member 2 modulators
CN111265528A (zh) 2020-01-21 2020-06-12 中国人民解放军军事科学院军事医学研究院 法匹拉韦在治疗冠状病毒感染方面的应用
WO2021183259A1 (en) * 2020-03-12 2021-09-16 Nanopharmaceutics, Inc. Famotidine and famotidine analogs for corona virus treatment
EP4137209A4 (en) * 2020-03-30 2023-08-30 Shandong Ruiying Pioneer Pharmaceuticals Co., Ltd. USE OF TFF2 PROTEIN AND IFN-? PROTEIN COMBINATION IN THE TREATMENT OF NOVEL CORONAVIRUS INFECTION
EP4089133A1 (en) * 2021-05-14 2022-11-16 Johannes Gutenberg-Universität Mainz Poly(ethylene glycol) having c1 to c3-alkyloxymethyl side chains, bioconjugates thereof, process for its preparation and its use.
CN113940310A (zh) * 2021-10-26 2022-01-18 浙江大学 一种小鼠胃癌模型的建立方法
CN116617363A (zh) * 2023-02-21 2023-08-22 中国海洋大学 人重组三叶因子TFF2-Fc在治疗炎症性肠病中的应用

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
CA1202840A (en) 1985-06-10 1986-04-08 Jonathan R. Kleinsasser Combination wet and dry feeder for animals
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4710384A (en) 1986-07-28 1987-12-01 Avner Rotman Sustained release tablets made from microcapsules
US5186933A (en) 1986-12-30 1993-02-16 Baylor College Of Medicine Synthesis and immunogenicity of rotavirus genes using a baculovirus expression system
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5194376A (en) 1989-02-28 1993-03-16 University Of Ottawa Baculovirus expression system capable of producing foreign gene proteins at high levels
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5846951A (en) 1991-06-06 1998-12-08 The School Of Pharmacy, University Of London Pharmaceutical compositions
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US20030186882A1 (en) * 2001-07-31 2003-10-02 Podolsky Daniel K. Methods and compositions for treating and preventing distal bowel lesions
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
TWI314933B (en) 2000-05-26 2009-09-21 Bristol Myers Squibb Compan Soluble ctla4 mutant molecules and uses thereof
US7052686B2 (en) 2000-09-29 2006-05-30 Schering Corporation Pegylated interleukin-10
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US7610156B2 (en) 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
CA2534995A1 (en) * 2003-07-31 2005-05-19 Anticancer, Inc. The use of plp with peg-rmetase in vivo for enhanced efficacy
US7524813B2 (en) * 2003-10-10 2009-04-28 Novo Nordisk Health Care Ag Selectively conjugated peptides and methods of making the same
WO2006034455A2 (en) * 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Polipeptide compounds for inhibiting angiogenesis and tumor growth
NZ556158A (en) * 2004-12-22 2010-04-30 Auckland Uniservices Ltd Trefoil factors and methods of treating proliferation disorders using same
JP2008525032A (ja) 2004-12-22 2008-07-17 アンブレツクス・インコーポレイテツド 組換えヒト成長ホルモンを発現及び精製するための方法
US8563521B2 (en) 2007-06-21 2013-10-22 Technische Universitat Munchen Biological active proteins having increased in vivo and/or in vitro stability
DK3178835T3 (da) 2009-02-03 2019-06-24 Amunix Pharmaceuticals Inc Forlængede rekombinante polypeptider og sammensætninger omfattende samme
CA2766039A1 (en) 2009-06-29 2011-01-20 The Board Of Regents Of The University Of Texas System Arginase formulations and methods
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
EP2536753B1 (en) 2010-02-16 2017-12-20 Novo Nordisk A/S Factor viii molecules with reduced vwf binding
DK2571510T3 (en) 2010-05-21 2018-11-19 Xl Protein Gmbh BIOSYNTHETIC PROLIN / ALANIN-RANDOM COIL POLYPEPTIDES AND THEIR APPLICATIONS
EP2575864A1 (en) * 2010-06-04 2013-04-10 Trifoilium ApS Trefoil factors (tff) for the treatment of chronic pulmonary diseases
EP3412314A1 (en) 2011-05-27 2018-12-12 Baxalta GmbH Therapeutic proteins conjugated to polysialic acid and methods of preparing same
WO2013176785A1 (en) * 2012-05-21 2013-11-28 The Trustees Of Columbia University In The City Of New York Trefoil family factor and uses thereof
CN107849102B (zh) 2015-05-15 2022-05-13 希望之城 嵌合抗原受体组合物
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
KR102469701B1 (ko) * 2016-09-13 2022-11-22 인트랙슨 액토바이오틱스 엔.브이. 점막부착성 미생물
WO2018132768A1 (en) 2017-01-13 2018-07-19 Sanna Pietro P Methods and compositions for treating hpa hyperactivity
US10174302B1 (en) 2017-06-21 2019-01-08 Xl-Protein Gmbh Modified L-asparaginase

Similar Documents

Publication Publication Date Title
US20230220034A1 (en) Method for improving solubility of protein and peptide by using immunoglogulin fc fragment linkage
Gebauer et al. Prospects of PASylation® for the design of protein and peptide therapeutics with extended half-life and enhanced action
TWI731015B (zh) 三重升糖素/glp-1/gip受體促效劑之長效接合物
AU690555B2 (en) Vitamin B-12 mediated oral delivery systems for GCSF and EPO
JP5653214B2 (ja) 細胞膜透過性ペプチド
EP2585098B1 (en) Fzd8 extracellular domains and fzd8 extracellular domain fusion molecules for use in treating obesity and obesity-related disorders
AU2015255834B2 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
CN104302772A (zh) 用于糖尿病治疗的蛋白、蛋白缀合物及其应用
JP7761557B2 (ja) グルカゴン、及びglp-1受容体及びgip受容体二重アゴニストを含む組成物及びその治療学的使用
CN1126441A (zh) 使用聚合物放大维生素b12吸收系统
CN104684576A (zh) 聚乙二醇化的oxm变体
JPH09506087A (ja) 改良されたインターフェロン−ポリマー複合体
CN113453703A (zh) 包括胰岛素和对胰高血糖素和glp-1和gip受体均具有活性的三重激动剂的药物组合物
JP2014510735A (ja) 部位特異的モノpeg化エキセンジン類似体およびその調製方法
CN111194223B (zh) 与白蛋白具有较佳结合亲和力的药物分子
JP2018517697A (ja) ペグ化オキシントモジュリン変異体
TW202415676A (zh) 升糖素樣肽-1受體拮抗劑
JP2022535685A (ja) ビオチン部分に結合した生理活性物質、及びその生理活性物質を含む経口投与用組成物
JP2026084695A (ja) グルカゴン、glp-1及びgip三重活性体の持続型結合体の液状製剤
US20250121086A1 (en) Liver-targeted substance and use thereof
RU2798085C2 (ru) Пролекарство, содержащее саморасщепляемый линкер
CN120475984A (zh) Dna-trail复合物及其治疗肿瘤的用途
BR112016022844B1 (pt) Método e composição para aperfeiçoar a solubilidade de proteína e peptídeo em solução aquosa que compreende um fragmento fc de imunoglobulina
EA040489B1 (ru) Способ улучшения растворимости белка и пептида за счет использования связывания с фрагментом fc иммуноглобулина
JP2019514859A (ja) 病的な筋肉減少および筋力低下の処置のためのnope